West Nile virus: Review of the literature

JAMA

Volumn 310, Issue 3, 2013, Pages 308-315

  Petersen, Lyle R ^a   Brault, Aaron C ^a   Nasci, Roger S ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CORTICOSTEROID; IMMUNOGLOBULIN; IMMUNOGLOBULIN M ANTIBODY; INSECT REPELLENT; JAPANESE ENCEPHALITIS VACCINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PESTICIDE; RIBAVIRIN; VIRUS RNA; WEST NILE VACCINE; YELLOW FEVER VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY CEREBROSPINAL FLUID LEVEL; ANTIBODY DETECTION; ARTHROPOD LARVA; BIRD DISEASE; BREEDING; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID LEVEL; CLINICAL FEATURE; CULEX QUINQUEFASCIATUS; DEATH; DISEASE COURSE; DISEASE SEVERITY; DISEASE SURVEILLANCE; ECOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC; FATALITY; FLACCID PARALYSIS; GEOGRAPHIC DISTRIBUTION; HUMAN; IMAGO; INCIDENCE; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; INSECT BITE; JAPANESE ENCEPHALITIS; LIMB WEAKNESS; MENTAL DISEASE; MORBIDITY; NONHUMAN; PARALYSIS; PATHOGENESIS; PEST MANAGEMENT; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; REVIEW; SEROLOGY; STANDARDIZATION; SYMPTOM; UNITED STATES; VECTOR CONTROL; VIREMIA; VIROLOGY; VIRUS CARRIER; VIRUS ENCEPHALITIS; VIRUS MENINGITIS; VIRUS TRANSMISSION; WEST NILE FEVER; WEST NILE FLAVIVIRUS; YELLOW FEVER;

EID: 84880308373     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.8042     Document Type: Review

References (75)

1. Nash D, Mostashari F, Fine A, et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med. 2001;344(24):1807- 1814. (Pubitemid 32538693)
2. Komar N, Langevin S, Hinten S, et al. Experimental infection of North American birds with the New York 1999 strain of West Nile virus. Emerg Infect Dis. 2003;9(3):311-322. (Pubitemid 36330872)
3. Kilpatrick AM, Daszak P, Jones MJ, et al. Host heterogeneity dominates West Nile virus transmission. Proc Biol Sci. 2006;273(1599):2327-2333.
4. Zou S, Foster GA, Dodd RY, et al. West Nile fever characteristics among viremic persons identified through blood donor screening. J Infect Dis. 2010;202(9):1354-1361.
5. Pealer LN, Marfin AA, Petersen LR, et al. Transmission of West Nile virus through blood transfusion in the United States in 2002. N Engl J Med. 2003;349(13):1236-1245. (Pubitemid 37152033)
6. Soverow JE, Wellenius GA, Fisman DN, Mittleman MA. Infectious disease in a warming world. Environ Health Perspect. 2009;117(7):1049-1052.
7. Kilpatrick AM, Meola MA, Moudy RM, Kramer LD. Temperature, viral genetics, and the transmission of West Nile virus by Culex pipiens mosquitoes. PLoS Pathog. 2008;4(6):e1000092.
8. Reisen WK, Fang Y, Martinez VM. Effects of temperature on the transmission of West Nile virus by Culex tarsalis (Diptera: Culicidae). J Med Entomol. 2006;43(2):309-317. (Pubitemid 44743542)
9. Bowden SE, Magori K, Drake JM. Regional differences in the association between land cover and West Nile virus disease incidence in humans in the United States. Am J Trop Med Hyg. 2011;84(2):234-238.
10. DeGroote JP, Sugumaran R. National and regional associations between human West Nile virus incidence and demographic, landscape, and land use conditions in the coterminous United States. Vector Borne Zoonotic Dis. 2012;12(8):657-665.
11. Hartley DM, Barker CM, Le Menach A, et al. Effects of temperature on emergence and seasonality of West Nile virus in California. Am J Trop Med Hyg. 2012;86(5):884-894.
12. Landesman WJ, Allan BF, Langerhans RB, et al. Inter-annual associations between precipitation and human incidence of West Nile virus in the United States. Vector Borne Zoonotic Dis. 2007;7(3):337-343. (Pubitemid 47536178)
13. Ruiz MO, Walker ED, Foster ES, Haramis LD, Kitron UD. Association of West Nile virus illness and urban landscapes in Chicago and Detroit. Int J Health Geogr. 2007;6:10.
14. Reisen WK, Takahashi RM, Carroll BD, Quiring R. Delinquent mortgages, neglected swimming pools, and West Nile virus, California. Emerg Infect Dis. 2008;14(11):1747-1749.
15. May FJ, Davis CT, Tesh RB, Barrett AD. Phylogeography of West Nile virus. J Virol. 2011;85(6):2964-2974.
16. Bondre VP, Jadi RS, Mishra AC, Yergolkar PN, Arankalle VA. West Nile virus isolates from India. J Gen Virol. 2007;88(pt 3):875-884.
17. Lanciotti RS, Roehrig JT, Deubel V, et al. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science. 1999;286(5448):2333-2337. (Pubitemid 30016893)
18. Davis CT, Ebel GD, Lanciotti RS, et al. Phylogenetic analysis of North American West Nile virus isolates, 2001-2004. Virology. 2005;342(2):252-265.
19. Lim PY, Behr MJ, Chadwick CM, Shi PY, Bernard KA. Keratinocytes are cell targets of West Nile virus in vivo. J Virol. 2011;85(10):5197-5201.
20. Schneider BS, Higgs S. The enhancement of arbovirus transmission and disease by mosquito saliva is associated with modulation of the host immune response. Trans R Soc Trop Med Hyg. 2008;102(5):400-408.
21. Cho H, Diamond MS. Immune responses to West Nile virus infection in the central nervous system. Viruses. 2012;4(12):3812-3830.
22. Sambri V, Capobianchi M, Charrel R, et al. West Nile virus in Europe. Clin Microbiol Infect. 2013.
23. Lindsey NP, Staples JE, Lehman JA, Fischer M. Surveillance for human West Nile virus disease. MMWR Surveill Summ. 2010;59(2):1-17.
24. Petersen LR, Hayes EB. West Nile virus in the Americas. Med Clin North Am. 2008;92(6):1307-1322; ix.
25. Weber IB, Lindsey NP, Bunko-Patterson AM, et al. Completeness of West Nile virus testing in patients with meningitis and encephalitis during an outbreak in Arizona, USA. Epidemiol Infect. 2011;140(9)1632-1636.
26. Petersen LR, Carson PJ, Biggerstaff BJ, et al. Estimated cumulative incidence of West Nile virus infection in US adults, 1999-2010 [published online ahead of print May 2012]. Epidemiol Infect. 2012:1-5.
27. Nett RJ, Kuehnert MJ, Ison MG, et al. Current practices and evaluation of screening solid organ donors for West Nile virus. Transpl Infect Dis. 2012;14(3):268-277.
28. O'Leary DR, Kuhn S, Kniss KL, et al. Birth outcomes following West Nile Virus infection of pregnant women in the United States: 2003-2004. Pediatrics. 2006;117(3):e537-e545. (Pubitemid 46063194)
29. Lim JK, Lisco A, McDermott DH, et al. Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS Pathog. 2009;5(2):e1000321.
30. Mostashari F, Bunning ML, Kitsutani PT, et al. Epidemic West Nile encephalitis, New York, 1999. Lancet. 2001;358(9278):261-264.
31. Brown JA, Factor DL, Tkachenko N, et al. West Nile viremic blood donors and risk factors for subsequent West Nile fever. Vector Borne Zoonotic Dis. 2007;7(4):479-488.
32. Carson PJ, Borchardt SM, Custer B, et al. Neuroinvasive disease and West Nile virus infection, North Dakota, USA, 1999-2008. Emerg Infect Dis. 2012;18(4):684-686.
33. Lindsey NP, Staples JE, Lehman JA, Fischer M. Medical risk factors for severe West Nile Virus disease, United States, 2008-2010. Am J Trop Med Hyg. 2012;87(1):179-184.
34. Murray K, Baraniuk S, Resnick M, et al. Risk factors for encephalitis and death from West Nile virus infection. Epidemiol Infect. 2006;134(6):1325-1332. (Pubitemid 44614956)
35. Bode AV, Sejvar JJ, Pape WJ, et al. West Nile virus disease: a descriptive study of 228 patients hospitalized in a 4-county region of Colorado in 2003. Clin Infect Dis. 2006;42(9):1234-1240.
36. Freifeld AG, Meza J, Schweitzer B, et al. Seroprevalence of West Nile virus infection in solid organ transplant recipients. Transpl Infect Dis. 2010;12(2):120-126.
37. Kumar D, Drebot MA, Wong SJ, et al. A seroprevalence study of West Nile virus infection in solid organ transplant recipients. Am J Transplant. 2004;4(11):1883-1888. (Pubitemid 39434451)
38. Rhee C, Eaton EF, Concepcion W, Blackburn BG. West Nile virus encephalitis acquired via liver transplantation and clinical response to intravenous immunoglobulin. Transpl Infect Dis. 2011;13(3):312-317.
39. Ferguson DD, Gershman K, LeBailly A, Petersen LR. Characteristics of the rash associated with West Nile virus fever. Clin Infect Dis. 2005;41(8):1204-1207. (Pubitemid 41429487)
40. Sejvar JJ, Curns AT, Welburg L, et al. Neurocognitive and functional outcomes in persons recovering from West Nile virus illness. J Neuropsychol. 2008;2(pt 2):477-499.
41. Sejvar JJ, Haddad MB, Tierney BC, et al. Neurologic manifestations and outcome of West Nile virus infection. JAMA. 2003;290(4):511-515. (Pubitemid 37430505)
42. Pepperell C, Rau N, Krajden S, et al. West Nile virus infection in 2002. CMAJ. 2003;168(11):1399-1405.
43. Burton JM, Kern RZ, Halliday W, et al. Neurological manifestations of West Nile virus infection. Can J Neurol Sci. 2004;31(2):185-193. (Pubitemid 38724810)
44. Sayao AL, Suchowersky O, Al-Khathaami A, et al. Calgary experience with West Nile virus neurological syndrome during the late summer of 2003. Can J Neurol Sci. 2004;31(2):194-203. (Pubitemid 38724811)
45. Robinson RL, Shahida S, Madan N, et al. Transient parkinsonism in West Nile virus encephalitis. Am J Med. 2003;115(3):252-253. (Pubitemid 37338156)
46. Kanagarajan K, Ganesh S, Alakhras M, et al. West Nile virus infection presenting as cerebellar ataxia and fever. South Med J. 2003;96(6):600-601. (Pubitemid 38281721)
47. Sejvar JJ, Bode AV, Marfin AA, et al. West Nile virus-associated flaccid paralysis. Emerg Infect Dis. 2005;11(7):1021-1027. (Pubitemid 40880900)
48. Jeha LE, Sila CA, Lederman RJ, et al. West Nile virus infection. Neurology. 2003;61(1):55-59.
49. Leis AA, Stokic DS. Neuromuscular manifestations of West Nile virus infection. Front Neurol. 2012;3:1-10.
50. Watson JT, Pertel PE, Jones RC, et al. Clinical characteristics and functional outcomes of West Nile fever. Ann Intern Med. 2004;141(5):360-365.
51. Sejvar JJ, Lindsey NP, Campbell GL. Primary causes of death in reported cases of fatal West Nile fever, United States, 2002-2006. Vector Borne Zoonotic Dis. 2011;11(2):161-164.
52. Emig M, Apple DJ. Severe West Nile virus disease in healthy adults. Clin Infect Dis. 2004;38(2):289-292. (Pubitemid 38113040)
53. Klee AL, Maidin B, Edwin B, et al. Long-term prognosis for clinical West Nile virus infection. Emerg Infect Dis. 2004;10(8):1405-1411. (Pubitemid 39014153)
54. Cook RL, Xu X, Yablonsky EJ, et al. Demographic and clinical factors associated with persistent symptoms after West Nile virus infection. Am J Trop Med Hyg. 2010;83(5):1133-1136.
55. Haaland KY, Sadek J, Pergam S, et al. Mental status after West Nile virus infection. Emerg Infect Dis. 2006;12(8):1260-1262.
56. Sadek JR, Pergam SA, Harrington JA, et al. Persistent neuropsychological impairment associated with West Nile virus infection. J Clin Exp Neuropsychol. 2010;32(1):81-87.
57. Carson PJ, Konewko P, Wold KS, et al. Long-term clinical and neuropsychological outcomes of West Nile virus infection. Clin Infect Dis. 2006;43(6):723-730. (Pubitemid 44330735)
58. Loeb M, Hanna S, Nicolle L, et al. Prognosis after West Nile virus infection. Ann Intern Med. 2008;149(4):232-241.
59. Berg PJ, Smallfield S, Svien L. An investigation of depression and fatigue post West Nile virus infection. S D Med. 2010;63(4):127-129; 131-133.
60. Murray K, Walker C, Herrington E, et al. Persistent infection with West Nile virus years after initial infection. J Infect Dis. 2010;201(1):2-4.
61. Baty SA, Gibney KB, Staples JE, et al. Evaluation for West Nile Virus (WNV) RNA in urine of patients within 5 months of WNV infection. J Infect Dis. 2012;205(9):1476-1477.
62. Gibney KB, Lanciotti RS, Sejvar JJ, et al. West Nile virus RNA not detected in urine of 40 people tested 6 years after acute West Nile virus disease. J Infect Dis. 2011;203(3):344-347.
63. Sejvar JJ, Bode AV, Marfin AA, et al. West Nile Virus-associated flaccid paralysis outcome. Emerg Infect Dis. 2006;12(3):514-516.
64. Lindsey NP, Sejvar JJ, Bode AV, et al. Delayed mortality in a cohort of persons hospitalized with West Nile virus disease in Colorado in 2003. Vector Borne Zoonotic Dis. 2012;12(3):230-235.
65. Tilley PA, Fox JD, Jayaraman GC, Preiksaitis JK. Nucleic acid testing for West Nile virus RNA in plasma enhances rapid diagnosis of acute infection in symptomatic patients. J Infect Dis. 2006;193(10):1361-1364. (Pubitemid 43673382)
66. Busch MP, Kleinman SH, Tobler LH, et al. Virus and antibody dynamics in acute West Nile virus infection. J Infect Dis. 2008;198(7):984-993.
67. Tyler KL, Pape J, Goody RJ, Corkill M, Kleinschmidt-De Masters BK. CSF findings in 250 patients with serologically confirmed West Nile virus meningitis and encephalitis. Neurology. 2006;66(3):361-365. (Pubitemid 43739937)
68. Gyure KA. West Nile virus infections. J Neuropathol Exp Neurol. 2009;68(10):1053-1060.
69. Beasley DW. Vaccines and immunotherapeutics for the prevention and treatment of infections with West Nile virus. Immunotherapy. 2011;3(2):269-285.
70. Diamond MS. Progress on the development of therapeutics against West Nile virus. Antiviral Res. 2009;83(3):214-227.
71. Zohrabian A, Hayes EB, Petersen LR. Cost-effectiveness of West Nile virus vaccination. Emerg Infect Dis. 2006;12(3):375-380.
72. Lothrop HD, Lothrop BB, Gomsi DE, Reisen WK. Intensive early season adulticide applications decrease arbovirus transmission throughout the Coachella Valley, Riverside County, California. Vector Borne Zoonotic Dis. 2008;8(4):475-489.
73. Macedo PA, Schleier JJ III, Reed M, et al. Evaluation of efficacy and human health risk of aerial ultra-low volume applications of pyrethrins and piperonyl butoxide for adult mosquito management in response to West Nile virus activity in Sacramento County, California. J Am Mosq Control Assoc. 2010;26(1):57-66.
74. Centers for Disease Control and Prevention. Human exposure to mosquito-control pesticides. MMWR Morb Mortal Wkly Rep. 2005;54(21):529-532.
75. Duprey Z, Rivers S, Luber G, et al. Community aerial mosquito control and naled exposure. J Am Mosq Control Assoc. 2008;24(1):42-46.